Novartis has signed an agreement with Pear Therapeutics to develop and commercialise prescription digital therapeutics for patients with substance and opioid use disorders.

A digital therapeutic is a software application intended to provide effective treatment for diseases and enhance clinical outcomes for patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal follows a similar collaboration between Novartis and Pear last month aimed at schizophrenia and multiple sclerosis patients.

Under the alliance, Sandoz, a subsidiary of Novartis, plans to combine its launching and commercialisation expertise with Pear’s experience in digital therapeutics design and implementation.

The partners will focus on Pear’s reSET digital therapeutic that was approved by the US Food and Drug Administration (FDA) in September last year for substance use disorder.

“The opioid crisis is taking a devastating and growing toll on our communities and we all have a role to play in helping find solutions.”

The companies will also work towards the commercialisation of reSET-O, after FDA approval, for opioid use disorder patients who are on buprenorphine therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sandoz CEO Richard Francis said: “The opioid crisis is taking a devastating and growing toll on our communities and we all have a role to play in helping find solutions that work for patients, families and communities.

“Our agreement with Pear and its expertise in developing prescription digital therapeutics fits with our strategy to be a part of the solution to the issues plaguing people battling addiction, including opioids.”

Digital therapeutics can be used as monotherapies or in conjunction with drug therapies, and have the potential to treat a variety of diseases.

Sandoz’s collaboration is part of its innovative digital health strategy aimed at developing technologies for several applications such as real-time data monitoring and better patient adherence.